Domestic and global drug pricing proposals. International trade and protection of intellectual property. Global supply chain issues. Proposals to expand access to HIV treatment and prevention therapies. Coverage and reimbursement policy for Hepatitis C, HIV and cancer. Issues related to triple negative breast cancer (TNBC) and early detection and screenings for breast cancer. 340B program reforms and changes.
2026 · 3rd Quarter (July 1 - Sep 30)
GILEAD SCIENCES, INC.
Filed by TODD STRATEGY GROUP.
Open official filingSource-reported fields
Filing overview
- Type
- 3rd Quarter - Report
- Posted
- Oct 19, 2026
- Income
- $80,000.00
- Expenses
- Not reported
- Registrant
- TODD STRATEGY GROUP
- Client
- GILEAD SCIENCES, INC.
- Filing UUID
- 5ba31335-799c-4842-a2ce-9b8500468efb
- Termination date
- Not reported
Literal source text
Lobbying issues and bill citations
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.